Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 193.22

+0.1%

1:17 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RXGOLF who wrote (24584)	8/18/1998 9:37:00 AM
From: Henry Niman	Read Replies (5) of 32384

Bear Stearns just reiterated its BUY (highest rating) on LGND today. They did note that "...the precipitous drop in Ligand's price suggests that there has been a negative fundamental change in the company for which we can find no evidence. Regulatory and clinical activities for Ligand's products continue on schedule, and we continue to believe that the company could reach profitability in 1999 on the heels of two oncology product launches. Based on this positive fundamental outlook, we continue to rate Ligand's shares at Buy and would recommend investors seriously examine the upside potential of this stock." They maintain the $0.09 profit for next year. 3Q is revised to a loss of $0.21 (was a loss of $0.10) and 4Q is revised to a loss of $0.02 from a gain of $0.03. For the year the loss is revised to $1.05 from $0.89. Second half highlights: Potential Panretin Topical approval - Nov Potential ONTAK approval - Dec LLY developmental decision on Targretin & RXRs - Dec Outlicense of non-US and non-European rights Other collaborations

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next